Two Regimens of SAR240550/Weekly Paclitaxel and Paclitaxel Alone as Neoadjuvant Therapy in Triple Negative Breast Cancer Patients (SOLTI NEOPARP)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01204125
Recruitment Status : Completed
First Posted : September 17, 2010
Last Update Posted : March 22, 2017
SOLTI Breast Cancer Research Group
Information provided by (Responsible Party):